Valuation: NovoCure Limited

Market Cap 1.8B 1.59B 1.47B 1.35B 2.54B 174B 2.59B 17.56B 6.86B 85.04B 6.77B 6.62B 295B P/E 2026 *
-9.61x
P/E 2027 * -15.4x
Enterprise Value 1.61B 1.41B 1.31B 1.21B 2.26B 155B 2.31B 15.66B 6.12B 75.84B 6.04B 5.91B 263B EV / Sales 2026 *
2.24x
EV / Sales 2027 * 1.89x
Free-Float
89.99%
Yield 2026 *
-
Yield 2027 * -
1 day+28.39%
1 week+24.70%
Current month+31.95%
1 month+46.88%
3 months+53.53%
6 months+40.87%
Current year+54.60%
1 week 15.2
Extreme 15.2
20.55
1 month 14.17
Extreme 14.17
20.55
Current year 9.82
Extreme 9.82
20.55
1 year 9.82
Extreme 9.82
20.55
3 years 9.82
Extreme 9.82
41.51
5 years 9.82
Extreme 9.82
188.94
10 years 5.95
Extreme 5.95
232.76
Manager TitleAgeSince
Chief Executive Officer 46 01/12/2025
Director of Finance/CFO 52 01/01/2025
Chief Tech/Sci/R&D Officer - 17/01/2023
Director TitleAgeSince
Director/Board Member 59 01/01/2012
Chairman 63 01/01/2009
Director/Board Member 64 05/08/2011
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Free

Director

268 0.0002%
30/06/26 Free

Chief Executive Officer

1,905 0.0016%
30/06/26 Free

General Counsel

1,299 0.0011%
Change 5-day change 1-year change 3-year change Capi.($)
+28.39%+24.70%+22.64%-48.64% 1.8B
+0.44%+0.37%+37.10%+4.72% 12.45B
-1.76%+10.89%+21.35%+19.35% 6.55B
-0.53%-1.99%+51.79%+21.11% 5.56B
0.00%+5.90% - - 4.59B
+2.14%+0.83%-27.36%+22.99% 4.38B
-1.76%-0.33%-22.06%-21.97% 4.11B
0.00%-6.35%-13.24%+219.26% 1.73B
+0.33%-0.33%+60.10%-3.17% 1.55B
+0.05%-7.35%-24.12%-52.96% 1.22B
Average +2.73%+0.85%+11.80%+17.85% 4.39B
Weighted average by Cap. +1.02%+2.37%+19.33%+13.58%

Financials

2026 *2027 *
Net sales 718M 631M 586M 539M 1.01B 69.36B 1.03B 7B 2.73B 33.87B 2.7B 2.64B 118B 784M 689M 640M 589M 1.1B 75.74B 1.13B 7.64B 2.98B 36.98B 2.94B 2.88B 128B
Net income -187M -164M -152M -140M -263M -18.02B -268M -1.82B -710M -8.8B -700M -685M -30.56B -111M -97.85M -90.84M -83.6M -157M -10.75B -160M -1.08B -423M -5.25B -418M -409M -18.23B
Net Debt -195M -171M -159M -146M -275M -18.83B -280M -1.9B -742M -9.2B -732M -716M -31.94B -317M -279M -259M -238M -446M -30.63B -455M -3.09B -1.21B -14.96B -1.19B -1.16B -51.95B
Logo NovoCure Limited
NovoCure Limited is a global oncology company with a proprietary platform technology called Tumor Treating Fields (TTFields), which are electric fields that exert physical forces to kill cancer cells via a variety of mechanisms. The Company's commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma. Its Optune Gio is approved by the FDA under the Premarket Approval pathway for the treatment of adult patients with newly diagnosed glioblastoma together with temozolomide, a chemotherapy drug, and for adult patients with GBM following confirmed recurrence after chemotherapy as monotherapy treatment. Its Optune Lua is approved by the FDA under the PMA pathway for the treatment of adult patients with metastatic non-small cell lung cancer concurrent with PD-1/PD-L1 inhibitors or docetaxel following progression on or after a platinum-based regimen.
Employees
1,605
Date Price Change Volume
23/07/26 $19.99 +28.39% 8,934,010
22/07/26 $15.57 -2.69% 1,064,781
21/07/26 $16.00 +0.38% 1,069,311
20/07/26 $15.94 +0.13% 933,512
17/07/26 $15.92 -3.05% 856,319
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
19.99USD
Average target price
25.43USD
Spread / Average Target
+27.21%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NVCR Stock